David Moller has joined Sigilon Therapeutics to become the company’s chief scientific officer. Moller comes to the Cambridge, MA, drug developer from Eli Lilly (NYSE: LLY), where he was vice president of business development for emerging technology and innovation. Last year, Sigilon raised $23.5 million in a Series A financing round to bring its technology for encapsulating therapeutic proteins into clinical testing.
From Our Editors · Special Report
Key indicators & expert insight from industry leaders
Xconomy
From Our Partners · Special Report
Advice for funding and future transformational opportunities
Xconomy Insight · Special Report
Insights, wisdom, and inspiration on what it takes
